Vertex Pharmaceuticals Incorporated(VRTX)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
VRTX | 141.42 B | 32.33x | 12.50% | 35.00% | $17.26 | 23.54% | 9.77 | - | $555.69 | $374.17 |
950160.KQ | 1.45 T | - | - | - | - | - | - | - | $149000.00 | $11470.00 |
ABBV | 459.82 B | 73.09x | 10.20% | 9.80% | $3.56 | - | - | 2.71% | $267.47 | $189.40 |
AMGN | 240.11 B | 27.60x | 9.50% | 22.95% | $16.09 | 91.47% | 4.90 | 2.33% | $447.03 | $262.49 |
950220.KQ | 17.27 B | - | 45.59% | - | - | -61.03% | 0.20 | - | $5465.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Vertex Pharmaceuticals Incorporated (VRTX) compared to its primary competitors (including 950160.KQ, ABBV, AMGN) reveals distinct metrics. VRTX trades at a valuation discount relative to its competitors, with a P/E ratio of 32.3x versus the peer average of 50.3x (representing a 36% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, VRTX's revenue growth of 12.5% lags behind the peer average of 21.8%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 35.0% compared to the peer average of 16.4%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• VRTX ranks #2 in P/E ratio, #2 in revenue growth, and #1 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $559.00 | $560.25 | $551.61 | $557.96 | 800,700 | -0.19% |
| 2026-09-02 | $552.42 | $558.36 | $549.07 | $556.75 | 1,734,500 | +0.78% |
| 2026-09-01 | $548.60 | $551.40 | $545.08 | $547.65 | 734,900 | -0.17% |
| 2026-08-31 | $535.38 | $546.84 | $532.23 | $544.52 | 1,198,300 | +1.71% |
| 2026-08-28 | $547.09 | $549.57 | $540.08 | $541.69 | 886,900 | -0.99% |
| 2026-08-27 | $540.08 | $550.83 | $540.08 | $547.55 | 843,900 | +1.38% |
| 2026-08-26 | $549.84 | $553.47 | $546.24 | $547.29 | 834,100 | -0.46% |
| 2026-08-25 | $545.53 | $555.69 | $543.75 | $552.85 | 775,000 | +1.34% |
| 2026-08-24 | $548.98 | $550.62 | $542.42 | $547.59 | 767,400 | -0.25% |
| 2026-08-21 | $545.10 | $555.32 | $540.70 | $548.05 | 1,074,900 | +0.54% |
| 2026-08-20 | $543.78 | $548.99 | $538.27 | $540.26 | 1,062,300 | -0.65% |
| 2026-08-19 | $537.47 | $553.69 | $532.55 | $552.06 | 1,437,300 | +2.71% |
| 2026-08-18 | $520.00 | $533.78 | $517.34 | $528.19 | 1,497,000 | +1.58% |
| 2026-08-17 | $503.87 | $517.84 | $502.53 | $515.55 | 1,111,200 | +2.32% |
| 2026-08-14 | $511.41 | $513.64 | $502.29 | $505.75 | 1,130,500 | -1.11% |
Explore More Analysis for VRTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.